5/31/2005 Temple Terrace, FL Stephanie Hayes The Kansas City Star (www.kansascity.com) Richard Preston's hookah pipe arrives at his table at the Meridian Hookah Lounge, and he takes a drag. The pipe, a centuriesold worldly tradition, is now on the lips of a 20-year-old heavy-metal enthusiast. Dressed in black, Preston sucks lemon-lime flavored tobacco smoke from a twisting tube and leans back, awash in the perfumed haze. He is mellow but talkative. "I worked my tail off today," says the Papa John's employee and University of Tampa student. "I come up here and it's like, "What's work?"' He shares the sofa with Jennifer Goubeaud, a 20-year-old University of South Florida psychology major. She smiles and sums up why college students are racing to try the hookah's sweet-tasting tobacco. "It's something good and legal to smoke," she says. The hookah, also known as the hubble-bubble or narghile, consists of a bowl connected to a vase of water with a long tube and mouthpiece. Shisha, a sticky, wet cocktail of tobacco, molasses and fruit, sits inside the bowl with a layer of foil and a hot coal on top. The smoke cools by passing through water. Between 200 and 300 hookah bars have opened in the country in the past five years, according to Smokeshop Magazine . Marc Karimi could be mistaken for a customer at Meridian. He has young skin, dark eyes and clean-cut hair. The 21-year-old nestles into a group of college students on a circular sofa. Karimi, a USF graduate, [...]

5/31/2005 Boston, MA Judy Foreman Boston Globe Within two years, you may be able to go for a regular dental visit, spit into a cup and, before your appointment is over, find out from an analysis of your saliva whether you're at risk for oral cancer. Currently, dentists have to do a thorough mouth exam to probe for this disease, which will strike more than 28,000 Americans this year and kill more than 7,000. Within a few more years, you may be able -- with a fancier spit test -- to find out if you're at risk for a number of other diseases, including breast cancer, type 2 diabetes, ovarian cancer, Alzheimer's disease, and rheumatoid arthritis. If you're among the avant garde, you might even have a tiny chip implanted in your cheek to monitor proteins in saliva such as C-reactive protein, which has been linked to an increased risk of heart disease. The chip could sound an alarm -- maybe a beep, maybe an electronic message to your doctor -- whenever levels of a particular protein drift too high or too low. Until a few years ago, the technology to analyze minute quantities of genetic material and proteins in saliva was not good enough for many of the tests doctors want to do or tests consumers could do in their homes, said Dr. David Wong, associate dean of research at the UCLA School of Dentistry. In the brave new world of genomics and proteomics -- the study of genes [...]

5/31/2005 New York, NY Scott Gottlieb, M.D. Forbes.com Cancer survival rates are climbing. Earlier detection is one reason. Another is the new medicines that created through recent innovations in biotechnology. Drugs today are more targeted to tumors, so patients are seeing their lives prolonged with fewer of the side effects that came with traditional cancer drugs. The hope for the future is even better. More than 400 new cancer drugs are in development. One of the clearest beneficiaries of recent innovations has been the field of breast cancer, where 15-year survival rates for early stage breast cancer patients have gone from one in ten to one in five in just the past decade With a series of new breast cancer drugs such as Bristol-Myers Squibb's Taxol, the aromatase inhibitors, Genentech's Herceptin and now Avastin (developed for colon cancer, it was recently shown to almost double the length of time women in late stages of breast cancer survive after chemotherapy), doctors are finally piecing together all of the new drugs they have into cocktails that are saving many more lives. Some experts now say that recent product launches for colon cancer, including ImClone's drug Erbitux, a similar drug made by Abgenix, another from Amgen and Genentech's Avastin, will mean similar gains for that cancer. The bottom line is clear: There's still far too much death and suffering from cancer, but investments in research are paying off. Relaxed regulatory standards at the Food and Drug Administration when it came to drugs that [...]

5/29/2005 Stockholm, Sweden Ivar Eckman New York Times Sweden is a few days from joining the select group of European countries that have banned smoking in restaurants and bars. But unlike Ireland, where the ban upset pub owners, or Italy, where cappuccino drinkers complained about having to smoke outdoors, no one here expects the June 1 event to be met with much protest. The main reason for this indifference is a four-letter word: snus. A moist, finely minced snuff tobacco inserted under the upper lip, snus is the Swedish alternative to cigarettes. The substance, which is prohibited in the rest of the European Union (Sweden got an exemption when it joined in 1995), has been used widely here for almost two centuries, and has grown in popularity in recent years. More than a million Swedes use it, and as smoking is banned in eating and drinking establishments, snus (pronounced snoos) is expected to become even more popular. "Historically, we've seen a lot of smokers switching to snus," said Sven Hindrikes, chief of Swedish Match, which made 95 percent of the almost 200 million cans of snus sold last year. "If you're not allowed to smoke in restaurants, it will have a positive effect on our sales." Swedish Match has been preparing for two years to take advantage of the smoking ban. New custom-made refrigerators and vending machines have been offered to restaurant and bar owners, and a sleek black "snustray" has been designed to replace ashtrays. (Because snus use stimulates [...]

5/29/2005 Australia Australian Bbroasting Co. News Online (abc.net.au) Smokers are being urged to kick the habit or risk developing life-threatening mouth cancers. The Australian Dental Association has issued the warning ahead of World No Tobacco Day, which falls on Tuesday. The association's Lena Lejmanoski says in Australia, 46 per cent of oral cancers in men and 36 per cent in women are caused by smoking. She says treatments for the cancers are distressing. "Radical surgery can be a form of treatment with radiotherapy involved," she said. "It can be very very disfiguring, giving them a severely compromised quality of life as far as their speech, their chewing and their swallowing." Ms Lejmanoski says smokers should get regular dental check-ups and look for early signs of the disease. "A white patch in the mouth, a lump in the mouth or any lesion in the mouth that doesn't heal," she said. "Early detection is very very important in basically helping to cure, give a potential cure for these cancers."

5/29/2005 Anaheim, CA Red Nova (www.rednova.com) Smokers who regularly took certain popular painkillers cut their risk of developing oral cancer but increased their chances of dying from heart-related problems, researcher say. The study raises fresh questions about the long-term use of Advil, Motrin and Aleve. The findings add to the suspicion that the heart risk extends beyond Cox-2 medications like Bextra, Vioxx and Celebrex to the larger family of pain relievers known as nonsteroidal anti- inflammatory drugs, or NSAIDs. These include ibuprofen and virtually all other over-thecounter pain pills except Tylenol or other brands of acetaminophen. Short-term use of NSAIDs -- two weeks or less -- for headaches or other pain is still considered safe. However, the study of smokers in Norway is the first evidence to support the recent U.S. Food and Drug Administration decision to warn about long-term use of all of these drugs except aspirin. Results were presented Monday at an American Association for Cancer Research meeting in Anaheim. Many doctors have switched patients to over-the-counter NSAIDs since the prescription drugs Vioxx and Bextra were pulled from the market. The doctors believed the over-thecounter drugs to be safer. Doctors in Norway wanted to see whether NSAIDs could prevent oral cancer because other work suggested they helped ward off other cancers. They found that heart risk was highest among ibuprofen users, who were nearly three times more likely to die of cardiovascular disease than non-NSAID users. Aspirin was the only NSAID that did not seem to raise the [...]

5/29/2005 Orlando, FL Charlene Laino WebMD Health New research shows that the popular cholesterol-lowering drugs called statins may slash a person's chance of developing breast, prostate, and lung tumors in half. Evidence continues to mount that cholesterol-lowering drugs called statins can reduce the risk of a variety of cancers. New research shows that the popular statin drugs may slash a person's chance of developing breast, prostate, and lung tumors in half. Three new studies show that "statins prevent healthy cells from transforming into cancerous cells," says researcher Ruby Kochhar, MD, a medical oncologist at the Naval Medical Center in Portsmouth, Va. "There was a protective effect in every type of cancer studied." The new studies were presented at the annual meeting of the American Society of Clinical Oncology (ASCO). Statins are one of the most widely prescribed drugs used in the U.S. to treat high cholesterol. They include medications such as Lescol, Lipitor, Mevacor, Pravachol, and Zocor and work by blocking the body's ability to produce cholesterol. Statins Reduce Breast, Lung, Prostate Risk In the studies presented, researchers collected health information on more than 1.4 million men and women from the Veterans Administration. The studies all took into account risk factors for the type of cancer being studied, including age, smoking, and alcohol use. For the breast cancer analysis, they compared statin use among 556 female veterans diagnosed with breast cancer and 39,865 women of similar ages without the disease. They show that statin use was associated with half the [...]

5/26/2005 Washington, D.C. Dr. J. Peter St. Clair Georgetown Record on (www2.townonline.com) About 30,000 Americans are diagnosed with oral and pharyngeal cancers each year. They account for 3 percent of all cancers diagnosed. More than a quarter of these patients will die from the disease. The percentage is high because many of these diagnoses are established at a late age. Those that see a dentist on a regular basis are more likely to get an early diagnosis because it is a routine part of the exam done by both hygienists and dentists. Tobacco factors into 75 percent of all cases. The concomitant use and/or abuse of alcohol seems to have a synergistic effect. It is thought that alcohol may increase the permeability of mucosal cells to the carcinogens in tobacco. Furthermore, alcohol may be metabolized into a known carcinogen. Most patients who are diagnosed are over age 45 years of age. There is an increasing group of patients who are younger, in the 20-30 year range. The male-female ratio is about 2:1 but the gap is narrowing. It has been found that individuals who have a diet rich in certain elements such as carotenoid compounds, selenium, folic acid, and vitamins A, C and E, as found in fresh fruits and vegetables, have a decreased incidence of oral cancers. Interestingly, smokers experience a diminished capacity to absorb these nutrients from their diet. Oral cancer occurs most frequently in the tongue, accounting for about 30 percent of all oral cancers. Cancers of [...]

5/26/2005 New York, NY press release U.S. Newswire (releases.usnewswire.com) Brian Hill, founder and executive director of the non-profit Oral Cancer Foundation has received the prestigious Strusser award from the New York University (NYU) College of Dentistry. The award was presented to him at the NYU graduation ceremonies at Madison Square Garden. This award is given annually, and recognizes an individual who has excelled in public service. In the audience, Eva Grayzel Cohen, an oral cancer survivor and an individual who has spoken on public service announcements for the American Dental Association related to oral cancer commented, "I was touched at the choice of Brian Hill, an oral cancer survivor, who has visible and audible repercussions from his treatments, to receive the Strusser award. Brian Hill's presence and honor was a powerful message to the graduating doctors, that it is imperative to give all patients an oral cancer screening, because the dental profession is the first line of discovery of this disease. Their active participation in the screening process, which results in early detection and treatment, can mean the difference of life or death to a patient. While his unscripted acceptance and comments to the audience were in his usual casual style, the message was serious. Choose to be involved, choose to make a difference". When asked about the presentation Hill commented, "Receiving an award like this from an institution the caliber of NYU, in a venue like the Garden, and having the opportunity to speak to this enormous crowd, is [...]